Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qian Xu has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Yuan Yuan

    Tumor Etiology and Screening Department of Cancer Institute, and Key Laboratory of Cancer Etiology and Prevention in Liaoning Education Department, the First Hospital of China Medical University, Shenyang, China

    15 shared publications
  • Li-Rong Yan

    Tumor Etiology and Screening Department of Cancer Institute and General Surgery, The First Hospital of China Medical University, Shenyang, People’s Republic of China

    12 shared publications
  • Han-Xi Ding

    Tumor Etiology and Screening Department of Cancer Institute and General Surgery, The First Affiliated Hospital of China Medical University, Key Laboratory of Cancer Etiology and Prevention, China Medical University, Liaoning Provincial Education Department, Shenyang, China

    9 shared publications
  • Zhi Lv

    Tumor Etiology and Screening Department of Cancer Institute and General Surgery, The First Hospital of China Medical University, Shenyang, People’s Republic of China

    9 shared publications
  • Ang Wang

    Tumor Etiology and Screening Department of Cancer Institute and General Surgery, The First Hospital of China Medical University, Shenyang, People’s Republic of China

    8 shared publications
  • Yuan Yuan

    The First Affiliated Hospital of China Medical University

    8 shared publications

Latest Publications

  • Open Access

    The molecular pathological basis and potential clinical applications of ‘zero‐budding’ status in stage II colorectal cancer

    by Ying‐Nan Liu, Ben Wang, Qian Xu

    In the personalized management of stage II colorectal cancer (CRC), traditional TNM (Tumor, Node, Metastasis) staging has limited ability to accurately stratify the risk of postoperative recurrence. Consequently, oncologists frequently face a major therapeutic dilemma when determining the use of adjuvant chemotherapy in these patients. Although tumor budding (TB) has been incorporated into international clinical guidelines as an independent prognostic marker associated with invasive potential, the conventional International Tumor Budding Consensus Conference classification system is primarily based on routine hematoxylin and eosin (H&E) staining. Furthermore, this framework classifies tumors with 0–4 buds into a single low‐risk category termed Bd1. This classification may obscure important biological differences between tumors with complete absence of cellular dissociation and those already showing early invasive activity. This review proposes separate diagnostic recognition of the ‘zero‐budding’ (Bd0) category. Recent large‐scale cohort studies and retrospective analyses support that Bd0 status, particularly when confirmed by pan‐cytokeratin immunohistochemistry, is associated with an extremely high negative predictive value for postoperative recurrence. At the subcellular level, the Bd0 category may reflect sustained suppression of the epithelial–mesenchymal transition process. Mechanistically, this relatively non‐invasive category may be maintained by preservation of the EBP50 scaffold, which stabilizes the membranous E‐cadherin/beta‐catenin complex and suppresses nuclear translocation of Wnt/beta‐catenin. Bd0 is also strongly associated with the deficient mismatch repair microenvironment, in which high tumor mutational burden may promote enhanced CD8 + T cell‐mediated immune surveillance capable of eliminating disseminating tumor cells before morphologic budding becomes detectable. This review summarizes the evolution of TB assessment, reviews the available clinical evidence supporting Bd0, evaluates emerging diagnostic approaches, and discusses the underlying molecular mechanisms.

  • Open Access

    Pepsinogen C Interacts with IQGAP1 to Inhibit the Metastasis of Gastric Cancer Cells by Suppressing Rho-GTPase Pathway

    by Hanxi Ding, Yingnan Liu, Xiaodong Lu, Aoran Liu, Qian Xu, Yuan Yuan

    Aim: This study systematically explored the biological effects and mechanisms of PGC on gastric cancer (GC) cells in vitro and in vivo. Method: The critical biological roles of PGC in GC were assessed via EdU staining, Hoechst staining, flow cytometry, mouse models, CCK-8, wound healing, transwell, and sphere-forming assays. The interaction study with IQ-domain GTPase-activating protein 1 (IQGAP1) was used by Liquid chromatography-mass spectrometry co-immunoprecipitation, immunofluorescence staining, CHX-chase assay, MG132 assay, and qRT-PCR. Results: PGC inhibited the proliferation, viability, epithelial–mesenchymal transition, migration, invasion, and stemness of GC cells and promoted GC cell differentiation. PGC suppressed subcutaneous tumor growth and peritoneal dissemination in vivo. The interaction study found PGC inhibits GC cell migration and invasion by downregulating IQGAP1 protein and IQGAP1-mediated Rho-GTPase signaling suppression. In addition, PGC disrupts the stability of the IQGAP1 protein, promoting its degradation and significantly shortening its half-life. Moreover, the expression levels of PGC and IQGAP1 in GC tissues were significantly negatively correlated. Conclusion: PGC may act as a tumor suppressor in the development and metastasis of GC. PGC can downregulate its interacting protein IQGAP1 and inhibit the Rho-GTPase pathway, thereby participating in the inhibition of GC cell migration and invasion.


  • Open Access

    Expression characteristics and their functional role of IGFBP gene family in pan-cancer

    by Yingnan Liu, Shixuan Shen, Ziwei Yan, Lirong Yan, Hanxi Ding, Ang Wang, Qian Xu, Liping Sun, Yuan Yuan

    Background: Insulin-like growth factor binding proteins (IGFBPs) are critical regulators of the biological activities of insulin-like growth factors. The IGFBP family plays diverse roles in different types of cancer, which we still lack comprehensive and pleiotropic understandings so far. Methods: Multi-source and multi-dimensional data, extracted from The Cancer Genome Atlas (TCGA), Oncomine, Cancer Cell Line Encyclopedia (CCLE), and the Human Protein Atlas (HPA) was used for bioinformatics analysis by R language. Immunohistochemistry and qRT-PCR were performed to validate the results of the database analysis results. Bibliometrics and literature review were used for summarizing the research progress of IGFBPs in the field of tumor. Results: The members of IGFBP gene family are differentially expressed in various cancer types. IGFBPs expression can affect prognosis of different cancers. The expression of IGFBPs expression is associated with multiple signal transduction pathways. The expression of IGFBPs is significantly correlated with tumor mutational burden, microsatellite instability, tumor stemness and tumor immune microenvironment. The qRT-PCR experiments verified the lower expression of IGFBP2 and IGFBP6 in gastric cancer and the lower expression of IGFBP6 in colorectal cancer. Immunohistochemistry validated a marked downregulation of IGFBP2 protein in gastric cancer tissues. The keywords co-occurrence analysis of IGFBP related publications in cancer showed relative research have been more concentrating on the potential of IGFBPs as tumor diagnostic and prognostic markers and developing cancer therapies. Conclusions: These findings provide frontier trend of IGFBPs related research and new clues for identifying novel therapeutic targets for various cancers.


  • Open Access

    Association of mitochondrial homeostasis and dynamic balance with malignant biological behaviors of gastrointestinal cancer

    by Ao-Ran Liu, Zhi Lv, Zi-Wei Yan, Xiao-Yang Wu, Li-Rong Yan, Li-Ping Sun, Yuan Yuan, Qian Xu

    Mitochondria determine the physiological status of most eukaryotes. Mitochondrial dynamics plays an important role in maintaining mitochondrial homeostasis, and the disorder in mitochondrial dynamics could affect cellular energy metabolism leading to tumorigenesis. In recent years, disrupted mitochondrial dynamics has been found to influence the biological behaviors of gastrointestinal cancer with the potential to be a novel target for its individualized therapy. This review systematically introduced the role of mitochondrial dynamics in maintaining mitochondrial homeostasis, and further elaborated the effects of disrupted mitochondrial dynamics on the cellular biological behaviors of gastrointestinal cancer as well as its association with cancer progression. We aim to provide clues for elucidating the etiology and pathogenesis of gastrointestinal cancer from the perspective of mitochondrial homeostasis and disorder.


  • Open Access

    Involvement of CXCL17 and GPR35 in Gastric Cancer Initiation and Progression

    by Yizhi Li, Aoran Liu, Songyi Liu, Lirong Yan, Yuan Yuan, Qian Xu

    The expression of CXC motif chemokine 17 (CXCL17) and its reported membrane receptor G-protein-coupled receptor 35 (GPR35) in different gastric pathological lesions and their clinical implications are largely unknown. In this study, a total of 860 pathological sections were immune-stained with either anti-CXCL17 or anti-GPR35 antibodies. Their expression was scored within the area of the normal gastric gland of non-atrophic gastritis (NAG-NOR), intestinal metaplasia of atrophic gastritis (AG-IM), IM adjacent to GC (GC-IM), and GC tissue. The clinical significance and potential function of CXCL17 and GPR35 were explored using multiple methods. Our results suggested that CXCL17 expression was gradually upregulated during the pathological progress of gastric diseases (NAG-NOR < AG-IM < GC-IM), but significantly downregulated when GC occurred. GPR35 had a similar expression pattern but its expression in GC remained abundant. High CXCL17 expression in GC was associated with less malignant behavior and was an independent biomarker of favorable prognosis. Overexpressing CXCL17 in HGC27 cells significantly upregulated CCL20 expression. TCGA analysis identified that CXCL17 was negatively correlated with some cancer-promoting pathways and involved in inflammatory activities. CTRP analysis revealed that gastric cell lines expressing less CXCL17 and were more sensitive to the CXCR2 inhibitor SB-225002.


  • Open Access

    Comprehensive Analysis and Validation of Solute Carrier Family 25 (SLC25) and Its Correlation with Immune Infiltration in Pan‐Cancer

    by Ao-Ran Liu, Ying-Nan Liu, Shi-Xuan Shen, Li-Rong Yan, Zhi Lv, Han-Xi Ding, Ang Wang, Yuan Yuan, Qian Xu

    As the largest gene family functioning in protein transport among human solute carriers, the SLC25 family (mitochondrial carrier family) can participate in development of cancer. However, a comprehensive exploration for the exactly roles of SLC family remains lacking. In the present study, a total of 15 functional SLC25 family genes were retrieved from all current publications. And multidimensional analyses were systematically performed based on the transcriptome and genome data of SLC25 family from a variety of online databases for their expression, immune cell infiltration, and cancer prognosis. Validation by qPCR and immunohistochemistry were further conducted for the expression of partial SLC25 family members in some tumor tissue. We found that the SLC25 family had strong correlation with immune cells, such as macrophages M2, CD8+ T cell, CD4+ T cell memory activated, and memory resting. Among them, SLC25A6 was most correlated with Macrophage M1 in uveal melanoma (r = −0.68, P = 1.9e − 0.5). Expression of mRNA level showed that SLC25A4 was downregulated in stomach adenocarcinoma and colon adenocarcinoma. SLC25A7 was highly expressed in stomach adenocarcinoma and colon adenocarcinoma. SLC25A23 was decreased in colon adenocarcinoma. qPCR and immunohistochemistry validation results were consistent with our bioinformatics prediction. SLC25A8 was associated with the prognosis of cancer. All these findings suggested that the SLC25 family might affects the immune microenvironment of the cancer and then had the potential to be predictive biomarkers for early diagnosis and prognosis as well as novel targets for individualized treatment of cancer.


  • Open Access

    Predicting Prognosis of Hepatocellular Carcinoma Patients Based on the Expression Signatures of Mitophagy Genes

    by Yan-Ke Li, Li-Rong Yan, Li-Yue Jiang, Qian Xu, Ben-Gang Wang

    Background. The unbalance of mitophagy was closely related to hepatocellular carcinoma (HCC) progression. At present, it has not been uncovered about the influence of mitophagy genes on HCC prognosis and their potential pathogenesis. Materials and Methods. The expression and clinical information of HCC in TCGA cohort were used to identify mitophagy differentially expressed genes (MDEGs) with prognostic value. The prognostic model of mitophagy genes was built and externally validated by LASSO regression in TCGA cohort and ICGC cohort, respectively. The function of the prognostic signature and its association with immune cell infiltration were explored. The profile of MDEGs was validated with 39 pairs HCC and paracarcinoma tissues by quantitative reverse transcription-PCR (qRT-PCR). Results. A total of 18 mitophagy genes that were upregulated and contributed to poor prognosis in HCC were identified. These genes could interact with each other. The correlation analysis showed that there was positively correlation among mitophagy genes. According to optimal value, 8 mitophagy gene signatures were involved in prognostic model. Based on median risk scores, HCC patients were divided into high-risk group and low-risk group. Compared with the low-risk group, the high-risk group has worse overall survival in TCGA cohort and ICGC cohort. The univariate and multivariate Cox regression analysis suggested that risk score was an independent prognostic factor of HCC patients. Time-dependent ROC curve was used to identify and validate good predicting performance of the prognostic model. Enrichment analysis showed that risk differentially expressed genes were enriched in various metabolism and cell division processes. The immune cell infiltration score and immune function were significantly different in two groups. qRT-PCR validation result showed that QSTM1, CSNK2B, PGAM5, and ATG5 were upregulated. Conclusion. Mitophagy genes could influence HCC progression through regulating the metabolism and immune functions and could be used to predict prognosis and considered as potential prognostic biomarker and precise therapeutic target of HCC.


  • Open Access

    RNA ‐sequencing reveals the expression profiles of tsRNAs and their potential carcinogenic role in cholangiocarcinoma

    by Yan‐Ke Li, Li‐Rong Yan, Ang Wang, Li‐Yue Jiang, Qian Xu, Ben‐Gang Wang

    Background: Recently, the incidence of cholangiocarcinoma (CCA) has gradually increased. As CCA has a poor prognosis, the ideal survival rate is scarce for patients. The abnormal expressed tsRNAs may regulate the progression of a variety of tumors, and tsRNAs is expected to become a new diagnostic biomarker of cancer. However, the expression of tsRNAs is obscure and should be elucidated in CCA. Methods: High‐throughput RNA sequencing technology (RNA‐seq) was utilized to determine the overall expression profiles of tsRNAs in three pairs CCA and adjacent normal tissues and to screen the tsRNAs that were differentially expressed. The target genes of dysregulated tsRNAs were predicted and the biological effects and potential signaling pathways of these target genes were explored by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Quantitative real‐time polymerase chain reaction (qRT‐PCR) was used to validate 11 differentially expressed tRFs with 12 pairs CCA and adjacent normal tissues. Results: High‐throughput RNA‐seq totally demonstrated 535 dysregulated tsRNAs, of which 241 tsRNAs were upregulated, such as tRF‐21‐YLKZKWE5D,tRF‐16‐9NF5W8B,tRF‐27‐78YLKZKWE52,tRF‐19‐RLXN48KP,tRF‐33‐IK9NJ4S2I7L7DV,tRF‐19‐F8DHXYIV, and 294 tsRNAs were downregulated (tRF‐20‐739P8WQ0, tRF‐34‐JJ6RRNLIK898HR, tRF‐17‐VL8RPY5, tRF‐23‐YP9LON4VDP, tRF‐39‐EH623K76IR3DR2I2, tRF‐17‐18YKISM, tRF‐19‐Q1Q89PJZ, etc.) in CCA compared with adjacent normal tissues (|log2 [fold change] | ≥ 1 and p value p = 0.021), and tRF‐20‐LE2WMK81 was upregulated in CCA ( p = 0.033). Conclusion: Differentially expressed tRFs in CCA are enriched in many pathways associated with neoplasms, which may impact the tumor progression and have potential to be diagnostic biomarkers and therapeutic targets of CCA.


  • Open Access

    Activating transcription factor 2 promotes the progression of hepatocellular carcinoma by inducing the activation of the WHSC1‐mediated TOP2A/PI3K/AKT axis

    by Zhong‐Ming Bao, Dan Yao, Xu Qian, Hua‐Guo Zhang, Ming Yang, Yun‐Hu Guo, Lei Qin

    Activating transcription factor 2 (ATF2) is a tumor driver gene implicated in several human malignancies. This study aimed to determine the roles of ATF2 and its related molecules in the tumorigenesis of hepatocellular carcinoma (HCC). According to the Pan‐cancer bioinformatics system, ATF2 is highly expressed in HCC. An increase in the expression of ATF2 was identified in clinically collected tumor tissues and procured HCC cells. The silencing of ATF2 reduced the viability, colony formation, invasion, and death resistance of HepG2 and SNU‐398 cells in vitro. ATF2 promoted the transcription of Wolf‐Hirschhorn syndrome candidate 1 (WHSC1) by binding to its promoter. WHSC1 further increased the expression of DNA topoisomerase II alpha (TOP2A) in HCC by inducing the dimethylation of histone H3 lysine 36 (H3K36me2) in the TOP2A promoter region. TOP2A activated the oncogenic PI3K/AKT signaling pathway. Further overexpression of WHSC1 activated the TOP2A/PI3K/AKT axis and restored the malignant behaviors of HCC cells suppressed by ATF2 silencing in vitro. In summary, this study demonstrated that, depending on WHSC1, ATF2 can activate the TOP2A/PI3K/AKT signaling cascade to promote the tumorigenesis of HCC. ATF2, WHSC1, and TOP2A may serve as potential targets in managing HCC.


  • Open Access

    The Involvement of CXCL17-GPR35 in Gastric Cancer Initiation and Development

    by Yi-Zhi Li, Ao-Ran Liu, Song-Yi Liu, Li-Rong Yan, Yuan Yuan, Qian Xu

    Background: C-X-C motif chemokine 17 (CXCL17), a newly identified chemokine, and its possible receptor, G-protein coupled receptor 35 (GPR35) were potential proteins involved in carcinogenesis; nevertheless, their involvement in gastric cancer (GC) initiation and development, which we aimed to evaluated in this study, remains undefined.Methods and materials: CXCL17 and GPR35 expressions in normal gastric gland of non-atrophic gastritis (NAG-NOR), intestinal metaplasia of atrophic gastritis (AG-IM), IM adjacent to GC (GC-IM), and GC tissues was determined by immunohistochemistry. Their possible roles were analyzed by the Cancer Genome Atlas (TCGA) data mining and western blot.Results: Either CXCL17 or GPR35 showed a strongest expression in GC-IM among the four types of tissues: CXCL17: GC-IM vs. AG-IM (P < 0.001), GC-IM vs. GC (P < 0.001); GPR35: GC-IM vs. AG-IM (P < 0.001), GC-IM vs. GC (P < 0.01). Their expressions were positively correlated in GC tissues (Spearman r = 0.2933, P < 0.001). CXCL17 expression was negatively correlated with the depth of tumor invasion (P = 0.015) and tumor maximum diameter (P = 0.003). Higher CXCL17 expression independently predicted for better survival in GC patients. TCGA analysis suggested CXCL17 expression was positively correlated with the transcriptional level of gastric mucosal maturation indicators TFF1, TFF2, PGC and MUC5AC, but negatively with the dedifferentiation indicators CDX1 and SFRP family members. Protein-protein interaction (PPI) revealed the potential connection of GPR35-CXCL17-CCL20. Overexpressing CXCL17 in HGC27 cell line downregulated SFRP2 and CDX1, but upregulated CCL20 expression.Conclusion: CXCL17 and GPR35 may play a vital role in GC initiation and development, especially in the IM to GC process. A higher CXCL17 expression independently predicted for better survival in GC patients, with a possible role in maintaining gastric mucosa maturation.